Westport, CT, United States of America

Hanno M Roder

This inventor holds 1 USPTO granted patent. Top assignee: Nad Ag. Active years: 2007.


Average Co-Inventor Count = 12.0

ph-index = 1


Company Filing History:


Years Active: 2007

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hanno M Roder: Innovator in Protein Kinase Inhibitors

Introduction

Hanno M Roder is a notable inventor based in Westport, CT (US). He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target various diseases.

Latest Patents

Hanno M Roder holds 1 patent for his invention titled "N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors." This invention focuses on N-carbacycle monosubstituted indolocarbazole compounds. The patent describes the use of these compounds in medicaments for treating non-insulin dependent diabetes mellitus, acute stroke, and other neurotraumatic injuries. Additionally, it addresses their application in treating diabetes mellitus, serving as chemotherapeutics for various malignant diseases, and targeting diseases caused by malfunctioning specific signaling pathways. The compounds are also relevant for treating neurodegenerative diseases, including Alzheimer's disease.

Career Highlights

Hanno M Roder has established himself as a key figure in his field through his innovative work. His research has the potential to impact the treatment of several serious health conditions, showcasing his commitment to advancing medical science.

Collaborations

Hanno collaborates with talented individuals such as Valerie Thillaye Du Boullay and Laura Casiraghi, contributing to a dynamic research environment.

Conclusion

Hanno M Roder's contributions to the field of protein kinase inhibitors highlight his role as an influential inventor. His work not only advances scientific knowledge but also holds promise for improving patient outcomes in various medical conditions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…